Overview

LeadArtis´s current business model includes the definition of an in-house pipeline and partnerships with other companies oriented to the combination of our technology with that of our collaborators.
 
Trimerbody® can be adapted to numerous protein configurations. There are multiple options to establish such relationships. Should you believe that our technology is of interest, we would be pleased to tell you more details and accommodate flexible avenues for collaboration schemes.  

Latest News

Clave Capital invests in Leadartis in a funding round of more than €1,600,000
14-05-2021

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its...

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis
30-04-2021

The entry of funds into leadartis' shareholding is part of a round of financing closed by...

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021